CN105796680B - Willow leaf meadow sweet stem branch resisting rheumatoid disease active component and its preparation method and application - Google Patents
Willow leaf meadow sweet stem branch resisting rheumatoid disease active component and its preparation method and application Download PDFInfo
- Publication number
- CN105796680B CN105796680B CN201610201656.9A CN201610201656A CN105796680B CN 105796680 B CN105796680 B CN 105796680B CN 201610201656 A CN201610201656 A CN 201610201656A CN 105796680 B CN105796680 B CN 105796680B
- Authority
- CN
- China
- Prior art keywords
- willow leaf
- stem branch
- active component
- meadow sweet
- glucopyranoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active components and its preparation method and application.The active component extracts through 60% alcohol reflux using willow leaf meadow sweet stem branch as raw material, ethyl alcohol is recovered under reduced pressure obtains extract, extract obtains total lignan glycosides effective part through purification with macroreticular resin.(+) -8'- hydroxyl rosin element -8'- in the active componentO- β-d- glucopyranoside, (7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O‑β-d- glucopyranoside and (+)-isolariciresinol -9-OThe sum of weight of-β-d- xylopyranose glucosides 40% ~ 50%.The present invention determines active component in the method that modern separation means and Pharmacological Activity Screening combine, gained active component is at distinguishing one from the other, active component content is high, and through inside and outside the experimental results showed that, willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component provided by the invention inhibits pro-inflammatory cytokine tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 generation to reach treatment rheumatoid arthritis effect.
Description
Technical field
The invention belongs to field of medicaments, are related to willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component and its preparation
Method further relates to willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component in preparation and treats rheumatoid arthritis product
In purposes.
Background technique
Rheumatoid arthritis be it is a kind of it is common with joint tissue chronic inflammation lesion be itself exempting from of mainly showing
Epidemic disease disease.Its main pathological change is articular synovial cells infiltration, and synovial membrane screen is formed, the erosion of cartilage and bone tissue.Class
The purpose of rheumatic arthritis treatment is to prevent disease, i.e. prevention arthritis and destruction process, prophylactic function is lost.Though
There are many right remedy measures, but drug therapy is still basis.Therapeutic agent includes non-steroidal anti-inflammatory, steroidal anti-inflammatory medicine and disease at present
Adjusting antirheumatic.It is continuous to the understanding of aetology mechanism with to inflammatory process, molecular genetics and biotech development
Deeply, researcher strives to find the therapeutic agent with specificity.Mainly it is as target spot, with inflammatory mediator using inflammatory cytokine
Target spot, using immunocompetent cell surface antigen as target spot, using signal transduction pathway as target spot.Cell factor is one group and is exempted from by body
The small-molecule substance that epidemic disease cell and the synthesis of nonimmune cell, secretion generate, has multiple biological function.With rheumatoid joint
Scorching closely related cell factor is most of to be secreted by monocyte, macrophage, fibroblast and T cell, wherein tumour
Necrosis factor-alpha, Interleukin -1β, interleukin-6 are virulence factor, and interleukin-10, interleukin-4 are protective factors.
Hao little Jiang study group is to rosaceae Spiraea pink blossom meadow sweet chemical component and bioactivity
The research of system.Pink blossom meadow sweetSpiraea japonicaL. f. variability is strong, has 7 mutation in China, constitutes one again
It is gregarious, including oval leaf mutationS. japonica var. ovalifolia Franch., anxious sharp mutationS. japonica
Var.acutaYu, tapering mutationS. japonica var. acuminateFranch., light leaf mutationS. japonica
var. fortunei(Planchon) Rehd., hairless mutationS. japonica var. Glabra (Rege1)
Koidz., star flower mutationS. japonicaVar.stellaris Rehd. with decomposite leaf mutationS. japonicavar.incisaYu).As traditional herbal medicine, pink blossom meadow sweet is mainly used for wind dispelling of catching a cold, hemostasis promoting blood circulation, cough-relieving of easing pain, improving eyesight benefit
Urine, irregular menstruation and are removed necrosis and promoted granulation at subdhing swelling and detoxicating.The chemical constitution study of the plant starts from 1964, the former Russian scholar
Frolova etc. reports the diterpene alkaloid component in the plant, between more than 30 years henceforth, the former Soviet Union, Japan and China
Scholar reports dozens of diterpene alkaloid and Diterpene in succession.Hao little Jiang study group is from 1987 to the domestic compound group
The chemical component of each mutation of plant has carried out the chemical research of system, and successively separation identifies 53 new diterpene and diterpene biology
Alkali, and find that this kind of alkaloid has anti-inflammatory, platelet aggregation-against and neuroprotective activity.Rosaceae Spiraea willow leaf
Meadow sweet is resourceful, and through retrieving to existing technical literature, but the research of its rare chemical component and pharmacological action is reported.
Summary of the invention
Inventor sends out in the research of Changbai Mountain Spiraea resource resisting rheumatoid arthritis screening active ingredients
On the basis of the existing potential resisting rheumatoid arthritis effect of willow leaf meadow sweet stem branch extract, using leading under activity index guidance
Active component and invalid target are determined to clastotype, has studied the main chemical compositions and content of active component, thus are completed
The present invention.
Object of the present invention is to overcome the deficiencies of the prior art and provide a kind of clear active principle, activity and mechanism clearly
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component, another object of the present invention are to provide the anti-class of willow leaf meadow sweet stem branch
The preparation method of rheumatic arthritis active component and the application in preparation treatment rheumatoid arthritis product.
In order to achieve the goal above, the technical scheme adopted by the invention is as follows:
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component of the invention is mentioned from willow leaf meadow sweet stem branch
The total lignan glycosides effective part of separation is taken, wherein (+) -8'- hydroxyl rosin element -8'-O- β-d- glucopyranoside, (7R,
8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O-β-d- pyrans
Glucoside and (+)-isolariciresinol -9-OThe sum of weight of-β-d- xylopyranose glucosides 40% ~ 50%, makes by the following method
Standby to obtain: willow leaf meadow sweet stem branch adds 60% alcohol reflux to extract three times, each dosage be by kilogram in terms of willow leaf meadow sweet stem branch weight
8 times of volumes in litres of amount, 2 hours every time, filtration, filtrate merged, and ethyl alcohol is recovered under reduced pressure and obtains extract, extract adds water to make
Dissolution, dosage be by kilogram in terms of 0.5 times of willow leaf meadow sweet stem branch weight volume in litres, through large pore resin absorption column D101
Chromatography, filling macroporous absorbent resin D101 volume be by kilogram in terms of 0.5 times of willow leaf meadow sweet stem branch weight volume in litres,
It is eluted with water closely colourless to eluent, discards eluent, it is closely colourless to eluent with 20% ethanol elution, eluent is discarded, is used
50% ethanol elution is closely colourless to eluent, collects eluent, is concentrated under reduced pressure, dry willow leaf meadow sweet stem branch resisting rheumatoid
Arthritis active component.
The present invention determines active component and invalid target using the guiding clastotype under activity index guidance, using macropore
It adsorbs resin D101 technology and 60% ethanol extract of willow leaf meadow sweet stem branch is separated into water elution position, 20% ethanol elution portion
Position, 50% alcohol elution and 95% alcohol elution, wherein 50% alcohol elution Freund's complete adjuvant is induced it is big
Mouse arthritis model primary inflammatory and secondary inflammation have apparent inhibiting effect.
Main component includes (+) -8'- hydroxyl in willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component of the invention
Base rosin element -8'-O- β-d- glucopyranoside, (7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranose
Glycosides, (+)-basilima sorbifolia Shu Huan lignanoid -9-O-β-d- glucopyranoside, (+)-isolariciresinol -9-O- β-d- xylopyranose
Glucosides, (+) -8'- hydroxyl rosin element -8'-O-α- l- arabopyranose glycosides and (+) -8'- hydroxyl rosin element -8'-O- β-d- pyrrole
It mutters xyloside.
The present invention is using modern separation identification technology to willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component
Study a point further separation identification, including (+) -8'- hydroxyl rosin element -8'-O- β-d- glucopyranoside [Kang H S, et
Al. Arch Pharm Res, 2003,26:24-27.], (+) -8'- hydroxyl rosin element -8'-O-α- l- arabopyranose glycosides
[noval chemical compound], (+) -8'- hydroxyl rosin element -8'-O- β-d- xylopyranose glucosides [noval chemical compound], (+)-basilima sorbifolia tree ring wood rouge
Element -9-O-β-d- glucopyranoside [Ono M, et al. J Nat Med, 2009,63:86-90.], (+)-different larch turpentine
Element -9-O- β-d- xylopyranose glucosides [Zhao Huanxin, waits Chinese medicine, 2010,33:1409-1411.], (-)-isolariciresinol-
9-O- β-d- xylopyranose glucosides [Zhao Huanxin, waits Chinese medicine, 2010,33:1409-1411.], (7S,8R) -3- methoxyl group -4',
7- epoxy -8,5'- new wood rouge alkane -3', 4,9,9'- tetrol 9-O- α-l- rhamnopyranosyloxyhy glucosides [Nakanishi T, et al.
Phytochemistry, 2004,65:207-213.] and (7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyra
Glucosides [Iida N, et al. Chem Pharm Bull, 2010,58:742-746.].
Chemical structure is as follows:
The present invention uses high effective liquid chromatography for measuring (+) -8'- hydroxyl rosin element -8'-O- β-d- glucopyranoside,
(7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O-β-d-
Glucopyranoside and (+)-isolariciresinol -9-OThe content of-β-d- xylopyranose glucosides.
The present invention provides the preparation method of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component, and this method includes
Following steps: willow leaf meadow sweet stem branch add 60% alcohol reflux extract three times, each dosage be by kilogram in terms of willow leaf meadow sweet stem branch
The volume in litres of 8 times of weight, 2 hours every time, filtration, filtrate merged, and ethyl alcohol is recovered under reduced pressure and obtains extract, extract adds water
Make to dissolve, dosage be by kilogram in terms of 0.5 times of willow leaf meadow sweet stem branch weight volume in litres, through large pore resin absorption column
D101 chromatography, filling macroporous absorbent resin D101 volume be by kilogram in terms of 0.5 times of willow leaf meadow sweet stem branch weight body in litres
Accumulated amount, is eluted with water closely colourless to eluent, discards eluent, closely colourless to eluent with 20% ethanol elution, discards elution
Liquid, it is closely colourless to eluent with 50% ethanol elution, eluent is collected, is concentrated under reduced pressure, dry the anti-class wind of willow leaf meadow sweet stem branch
Wet arthritis active component.
The preparation method of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component provided by the invention, preparation have
Imitate (+) -8'- hydroxyl rosin element -8'- in positionO- β-d- glucopyranoside, (7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O-β-d- glucopyranoside and (+)-different larch turpentine
Element -9-OThe sum of weight of-β-d- xylopyranose glucosides 40% ~ 50%.
The preparation method of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component provided by the invention is from willow leaf
The total lignan glycosides effective part of separation is extracted in meadow sweet stem branch, main component includes (+) -8'- hydroxyl rosin element -8'-O-
β-d- glucopyranoside, (7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside, (+)-basilima sorbifolia tree
Ring lignanoid -9-O-β-d- glucopyranoside, (+)-isolariciresinol -9-O- β-d- xylopyranose glucosides, (+) -8'- hydroxyl
Rosin element -8'-O-α- l- arabopyranose glycosides and (+) -8'- hydroxyl rosin element -8'-O- β-d- xylopyranose glucosides.
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component of the invention treats rheumatoid joint in preparation
It is applied in scorching product, is especially preparing pro-inflammatory cytokine tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 generation
It is applied in inhibitor product.
Model of adjuvant arthritis in rats is the classical mould evaluating resisting rheumatoid disease arthritis drug and acting on immune inflammation
Type, after injecting Freund's complete adjuvant sensitization in rat toes, lesion is divided into primary and two kinds secondary: novo lesions
It is mainly shown as that early stage causes the inflammatory reaction of scorching part, 18 days right foot swelling reach to peak values after cause is scorching gradually mitigate after continuing 3 days；
Secondary arthritis comes across after cause inflammation 15 days or so, shows as the swelling of opposite side (left hind) and forelimb foot, and ear and tail portion occur
" arthritis " brief summary, allergic pannus and weight loss etc..Cell factor is one group by immune cell and nonimmune
The small-molecule substance that cell synthesis, secretion generate, has multiple biological function.With closely related thin of rheumatoid arthritis
Intracellular cytokine is most of to be secreted by monocyte, macrophage, fibroblast and T cell, wherein tumor necrosis factor-alpha, Bai Jie
- 1 β of element and interleukin-6 are virulence factor, and interleukin-4 and interleukin-10 are protective factors.Tumor necrosis factor-alpha is a kind of
Cell factor with multiple biological activities, is mostly derived from monocyte and macrophage.Mature tumor necrosis factor-alpha point
Son amount is about 17kd, is divided into cross-module type and secreting type, with trimeric form in conjunction with cell surface receptor.Tumor necrosis factor-alpha
Synovial cell and cartilage cell is promoted to synthesize and discharge prostaglandin E2And clostridiopetidase A, cause the absorption of bone and cartilage to destroy, promotees
Into the hyperplasia of fibroblast；Promote the absorption of proteoglycan in cartilage and inhibit its synthesis, makes cartilage degradation；In activity
The activity and aggregation of blood platelet can be improved in rheumatoid arthritis, and fibroblast is promoted to discharge adhesion molecule such as cell adhesion
Molecule.Interleukin-1 is mainly by monocyte and macrophages secrete.In the serum and joint fluid of patient with rheumatoid arthritis
High-caliber interleukin-1, horizontal activity and tectology feature such as synovial hyperplasia, leucocyte with disease can be detected
Infiltration etc. is closely related.Interleukin-1 adjusts the expression of cytokine profiles, cell adhesion molecule, immune modulatory molecules, in class
It plays a significant role in the bone erosion and cartilage destruction of rheumatic arthritis.Interleukin-1 promotes synovial cell and lymphocyte
Proliferation and differentiation, promote synovial cell and cartilage cell to synthesize and discharge prostaglandin E2 and clostridiopetidase A, prostaglandin E2 and glue
Protoenzyme can cause the disintegration of the inflammatory reaction of synovial membrane, cartilage matrix, cause joint injury, and the immune complex of part and free
The decomposition products stimulation interleukin-1 such as collagen synthesis；Interleukin-1 stimulates synovial cell to generate high-caliber matrix metal egg
White enzyme inhibits joint collagen and proteoglycan synthesis, leads to the destruction and reconstruction of extracellular matrix, accelerate rheumatoid joint
Scorching destruction process；Interleukin-1 stimulates fibroblast, endotheli ocytosis, promotes synovial membrane to thicken and is formed with pannus.It is white
Interleukin -6 is generated by T lymphocyte, monocyte and fibroblast, is had in inflammatory cytokine network and Immune Regulative Network
There is critical effect.Interleukin-6 induces acute phase reactive protein such as c reactive protein；Induction B cell is divided into can IgG secretion
The thick liquid cell of type antibody；Mediate the generation of the prostanoid factor.Willow leaf embroider line is studied using model of adjuvant arthritis in rats
The effect of chrysanthemum stem branch resisting rheumatoid arthritis active component, the results showed that, willow leaf meadow sweet stem branch resisting rheumatoid arthritis
1000 mgkg of active component-1Dosage group has obvious inhibition to make adjuvant arthritic rats primary inflammatory and secondary inflammation
With；It is closed using lipopolysaccharide-induced 264.7 model of mouse macrophage strain RAW research willow leaf meadow sweet stem branch resisting rheumatoid
It saves scorching active component and inhibiting effect, knot is generated to pro-inflammatory cytokine tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Fruit shows that willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component can obviously inhibit lipopolysaccharide-induced mouse huge thermophilic thin
264.7 pro-inflammatory cytokine tumor necrosis factor-alpha of born of the same parents strain RAW, Interleukin -1β and interleukin-6 generate.The above results table
Bright willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component can be applied in preparation treatment rheumatoid arthritis product,
It is controlled especially as pro-inflammatory cytokine tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 formation inhibitor in preparation
It treats and is applied in rheumatoid arthritis product.Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component can also be contained
Pharmaceutical composition is applied in preparation treatment rheumatoid arthritis product, especially as pro-inflammatory cytokine neoplasm necrosis
The factor-α, Interleukin -1β and interleukin-6 formation inhibitor are applied in preparation treatment rheumatoid arthritis product.
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component advantage of the invention be with modern separation means and
The method that Pharmacological Activity Screening combines determines active component, and for gained active component at distinguishing one from the other, active component content is high, and passes through
Inside and outside the experimental results showed that, willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component provided by the invention obviously inhibits
Pro-inflammatory cytokine tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 generation reach treatment rheumatoid arthritis and make
With, willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component provided by the invention can be convenient with it is pharmaceutically acceptable
Carrier is prepared into the drug of various dosage forms, and clinic is facilitated to take.
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis preparation method advantage of the invention is simple process, operation side
Just, technology is easily grasped, and energy consumption is small, and solvent is recyclable to be recycled, and production cost is low.
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component of the invention can be used for preparing treatment resisting rheumatoid disease
Property arthritis product advantage it is clear for mechanism of action, based on inhibiting pro-inflammatory cytokine tumor necrosis factor-alpha, Interleukin -1β
It is generated with interleukin-6.
The present invention also provides with willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component of the invention and pharmacy
Upper acceptable carrier or the pharmaceutical preparation of excipient preparation.These pharmaceutical preparations be selected from following dosage form: tablet, sugar coated tablet,
Film coated tablet, enteric coated tablet, effervescent tablet, sublingual tablets, capsule, hard capsule, soft capsule, microcapsules, microballoon
Agent, granule, pill, pill, powder, paste, oral solution, suspension, solution, aerosol, injection, emulsion for injection,
Freeze-dried powder can also be prepared into sustained release or controlled release preparation as needed.
Of the invention contains willow leaf meadow sweet stem branch resisting rheumatoid arthritis effective fraction medicine preparation, is preparing drug
Pharmaceutically acceptable carrier can be added when preparation, the pharmaceutically acceptable carrier comes from: antioxidant, chelating agent, surface-active
Agent, filler, disintegrating agent, wetting agent, solvent, slow-release material, enteric material, pH adjusting agent, corrigent, pigment etc. are commonly used and are carried
Body is such as: mannitol, dextran, lactose, glucose, sorbierite, xylitol, water for injection, injection ethyl alcohol, sodium chloride,
Silicon derivative, cellulose, cellulose derivative, gelatin, polyvinylpyrrolidone, glycerol, Tween 80, agar, calcium carbonate, poly- second
Glycol, cyclodextrin, phospholipid material, talcum powder, magnesium stearate, calcium stearate etc..
Oral dose changes, dose according to the age of patient, weight, coincident with severity degree of condition and other similar factor
40 ~ 60 mg based on the daily willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component weight of every 1 kg body weight, point 3 clothes
With.
Below by way of specific embodiment, the present invention is further illustrated, not limitation of the invention, according to ability
The prior art well known to domain, embodiments of the present invention are not limited to specific embodiment.
Specific embodiment
Embodiment 1
The screening of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component
The preparation of willow leaf meadow sweet stem branch extract and separated part: 10 Kg of willow leaf meadow sweet stem branch adds 60% ethyl alcohol to return
Stream extracts three times, and each dosage is 80L, and 2 hours every time, filtration, filtrate merged, and ethyl alcohol is recovered under reduced pressure and obtains extract, extract
Water is added to make to dissolve, dosage 5L, through large pore resin absorption column D101 chromatography, filling macroporous absorbent resin D101 volume is 5L, is used
Water elution is closely colourless to eluent, collects eluent, is concentrated under reduced pressure, dry 475 g of willow leaf meadow sweet stem branch water elution position；
It is closely colourless to eluent with 20% ethanol elution, eluent is collected, is concentrated under reduced pressure, it is dry that 20% ethyl alcohol of willow leaf meadow sweet stem branch is washed
De- 111 g of position；It is closely colourless to eluent with 50% ethanol elution, eluent is collected, is concentrated under reduced pressure, dry willow leaf meadow sweet
50% alcohol elution of stem branch, 342 g；It is closely colourless to eluent with 95% ethanol elution, eluent is collected, is concentrated under reduced pressure, it is dry
Obtain 95% alcohol elution of willow leaf meadow sweet stem branch, 212 g.
Each separated part of willow leaf meadow sweet stem branch extract is to adjuvant arthritic rats primary inflammatory and secondary inflammation
Influence: in addition to Normal group, every group of right hind foot of rat toe it is intradermal injection containing inactivation H37RV Mycobacterium hominis atoleine cream
0.1 ml(8 mgH of agent37RV Mycobacterium hominis/ml atoleine), Normal group injects 0.1ml atoleine.Modeling rat
60, it is divided into 6 groups, respectively model control group, tripterygium glycosides (25 mg/kg) group, the washing of willow leaf meadow sweet stem branch at random
De- position (1000 mg/kg) group, willow leaf meadow sweet stem branch 20% alcohol elution (1000 mg/kg) group, willow leaf meadow sweet stem
Branch 50% alcohol elution (1000 mg/kg) group, willow leaf meadow sweet stem branch 95% alcohol elution (1000 mg/kg) group.
Continuous gavage (ig) is administered 21 days after each group allergized rats, and Normal group and model control group give same volume (10 ml/kg)
Distilled water.Toes volume, difference before and after calculating swelling observe drug to original to each group rat behind the right side of measurement in 3 days and 5 days after sensitization
The influence of hair property inflammation.It the results are shown in Table table 1.The result shows that 50% alcohol elution of willow leaf meadow sweet stem branch is to adjuvant arthritis
Rat primary inflammation has obvious inhibiting effect, tripterygium glycosides, willow leaf meadow sweet stem branch water elution position, willow leaf meadow sweet stem
20% alcohol elution of branch and the effect of 95% alcohol elution of willow leaf meadow sweet stem branch are unobvious.Each group rat is 17 after sensitization
It observes influence of the drug to secondary inflammation with left back toes volume, difference before and after calculating swelling is measured within 21 days.It the results are shown in Table
2.The result shows that 50% alcohol elution of willow leaf meadow sweet stem branch has obvious inhibition to adjuvant arthritic rats secondary inflammation
Effect, willow leaf meadow sweet stem branch water elution position, willow leaf meadow sweet stem branch 20% close with 25 mg/kg of tripterygium glycosides effect
Alcohol elution and the effect of 95% alcohol elution of willow leaf meadow sweet stem branch are unobvious.
Influence of the 1 each separated part of willow leaf meadow sweet stem branch extract of table to adjuvant arthritic rats primary inflammatory
Compare with model control group:**P < 0.01
Influence of the 2 each separated part of willow leaf meadow sweet stem branch extract of table to adjuvant arthritic rats secondary inflammation
Compare with model control group:**P < 0.01
Embodiment 2
HPLC method measures (+) -8'- hydroxyl rosin element-in willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component
8'-O- β-d- glucopyranoside, (7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside, (+)-pearl
Hua Shuhuan lignanoid -9-O-β-d- glucopyranoside and (+)-isolariciresinol -9-O- β-d- xylopyranose Glycosides Contents
Method
Chromatographic condition and system suitability
Using octadecylsilane chemically bonded silica as filler；Using acetonitrile as mobile phase A, using 0.1 phosphoric acid solution as mobile phase
B, linear gradient elution: 0 min(A 10%, B 90%, volume ratio) → 10 min(A 10%, B 90%, volume ratio) → 30
Min(A 30%, B 70%, volume ratio) → 60 min(A 30%, B 70%)；Flow velocity: 1.0 mLmin-1；Detection wavelength is 280
nm.Theoretical cam curve presses (+) -8'- hydroxyl rosin element -8'-O- β-d- glucopyranoside calculates, and is not less than 6000.
The preparation of solution
The preparation of reference substance solution
Precision weighs (+) -8'- hydroxyl rosin element -8'-O- β-d- glucopyranoside, (7R,8SThe double pines of)-dihydro dehydrogenation
Cypress alcohol -9'-O- β-d- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O-β-d- glucopyranoside and (+)-are different
Lariciresinol -9-O- β-d- xylopyranose glucosides reference substance is appropriate, adds methanol that every 1 mL is made containing (+) -8'- hydroxyl rosin element -
8'-O- β-d- glucopyranoside 40μg、(7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside 40μ
G, (+)-basilima sorbifolia Shu Huan lignanoid -9-O-β-d- glucopyranoside 40μG and (+)-isolariciresinol -9-O- β-d- pyrrole
It mutters xyloside 100μThe solution of g.
The preparation of test solution
50 mg of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component is taken, it is accurately weighed, add methanol to dissolve, turns
It moves in 100 ml measuring bottles, adds methanol to scale, shake up, filter, take subsequent filtrate as test solution.
Sample measuring method
Precision draws test solution and control solution each 20μL is measured, one point external standard method meter by chromatographic condition sample introduction
Calculate (+) -8'- hydroxyl rosin element -8'- in willow leaf meadow sweet stem branch resisting rheumatoid arthritis active componentO- β-d- glucopyra
Glucosides, (7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O-
β-d- glucopyranoside and (+)-isolariciresinol -9-OThe content of-β-d- xylopyranose glucosides.
Embodiment 3
10 prosperous of the place of production Kg(Jilin of willow leaf meadow sweet stem branch), add 60% alcohol reflux to extract three times, each dosage is
80L, 2 hours every time, filtration, filtrate merged, and ethyl alcohol is recovered under reduced pressure and obtains extract, and extract adds water to make to dissolve, dosage 5L, warp
Large pore resin absorption column D101 chromatography, filling macroporous absorbent resin D101 volume are 5L, and, abandoning closely colourless to eluent is eluted with water
Eluent is removed, it is closely colourless to eluent with 20% ethanol elution, eluent is discarded, it is closely colourless to eluent with 50% ethanol elution,
Eluent is collected, is concentrated under reduced pressure, dry 342 g of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component.Using reality
Apply the method measurement of example 2, (+) -8'- hydroxyl rosin element -8'- containing 7.69% weightO- β-d- glucopyranoside, 12.17%
(the 7 of weightR,8S)-dihydro dehydrodiconiferyl alcohol -9'-O(+)-basilima sorbifolia tree of-β-d- glucopyranoside, 9.86% weight
Ring lignanoid -9-O-(+)-isolariciresinol -9- of β-d- glucopyranoside and 20.16% weightO- β-d- xylopyranose
Glycosides.
Embodiment 4
10 place of production Kg(Changbai of willow leaf meadow sweet stem branch), add 60% alcohol reflux to extract three times, each dosage is
80L, 2 hours every time, filtration, filtrate merged, and ethyl alcohol is recovered under reduced pressure and obtains extract, and extract adds water to make to dissolve, dosage 5L, warp
Large pore resin absorption column D101 chromatography, filling macroporous absorbent resin D101 volume are 5L, and, abandoning closely colourless to eluent is eluted with water
Eluent is removed, it is closely colourless to eluent with 20% ethanol elution, eluent is discarded, it is closely colourless to eluent with 50% ethanol elution,
Eluent is collected, is concentrated under reduced pressure, dry 403 g of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component.Using reality
Apply the method measurement of example 2, (+) -8'- hydroxyl rosin element -8'- containing 9.83% weightO- β-d- glucopyranoside, 8.02%
(the 7 of weightR,8S)-dihydro dehydrodiconiferyl alcohol -9'-O(+)-basilima sorbifolia tree of-β-d- glucopyranoside, 4.29% weight
Ring lignanoid -9-O-(+)-isolariciresinol -9- of β-d- glucopyranoside and 18.70% weightO- β-d- xylopyranose
Glycosides.
Embodiment 5
10 place of production Kg(Jilin Erdaobaihe River of willow leaf meadow sweet stem branch), add 60% alcohol reflux to extract three times, each dosage
For 80L, 2 hours every time, filtration, filtrate merged, and ethyl alcohol is recovered under reduced pressure and obtains extract, and extract adds water to make to dissolve, dosage 5L,
Through large pore resin absorption column D101 chromatography, filling macroporous absorbent resin D101 volume is 5L, be eluted with water it is closely colourless to eluent,
Eluent is discarded, it is closely colourless to eluent with 20% ethanol elution, eluent is discarded, with 50% ethanol elution to the nearly nothing of eluent
Color collects eluent, is concentrated under reduced pressure, dry 333 g of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component.Using
The method of embodiment 2 measures, (+) -8'- hydroxyl rosin element -8'- containing 8.25% weightO- β-d- glucopyranoside,
(the 7 of 10.93% weightR,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside, (+)-of 5.22% weight are precious
Pearl head-ornaments Shu Huan lignanoid -9-O-(+)-isolariciresinol -9- of β-d- glucopyranoside and 19.17% weightO- β-d- pyrrole
It mutters xyloside.
Embodiment 6
10 place of production Kg(Jilin Fusong of willow leaf meadow sweet stem branch), add 60% alcohol reflux to extract three times, each dosage is
80L, 2 hours every time, filtration, filtrate merged, and ethyl alcohol is recovered under reduced pressure and obtains extract, and extract adds water to make to dissolve, dosage 5L, warp
Large pore resin absorption column D101 chromatography, filling macroporous absorbent resin D101 volume are 5L, and, abandoning closely colourless to eluent is eluted with water
Eluent is removed, it is closely colourless to eluent with 20% ethanol elution, eluent is discarded, it is closely colourless to eluent with 50% ethanol elution,
Eluent is collected, is concentrated under reduced pressure, dry 385 g of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component.Using reality
Apply the method measurement of example 2, (+) -8'- hydroxyl rosin element -8'- containing 10.26% weightO- β-d- glucopyranoside, 6.58%
(the 7 of weightR,8S)-dihydro dehydrodiconiferyl alcohol -9'-O(+)-basilima sorbifolia tree of-β-d- glucopyranoside, 7.33% weight
Ring lignanoid -9-O-(+)-isolariciresinol -9- of β-d- glucopyranoside and 19.68% weightO- β-d- xylopyranose
Glycosides.
Embodiment 7
The separation and identification of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component chemical component
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component is separated through ODS column chromatography and preparative liquid chromatography
To 8 compounds, using ESI-MS,1H-NMR、13The structure of C-NMR, HSQC, HMBC and CD data authentication compound is (+)-
8'- hydroxyl rosin element -8'-O- β-d- glucopyranoside (1), (+) -8'- hydroxyl rosin element -8'-O-α- l- pyrans is Arabic
Glucosides (2), (+) -8'- hydroxyl rosin element -8'-O- β-d- xylopyranose glucosides (3), (+)-basilima sorbifolia Shu Huan lignanoid -9-O-β-
D- glucopyranoside (4), (+)-isolariciresinol -9-O- β-d- xylopyranose glucosides (5), (-)-isolariciresinol -9-O- β-d- xylopyranose glucosides (6), (7S,8R) -3- methoxyl group -4', 7- epoxy -8,5'- new wood rouge alkane -3', 4,9,9'- tetrol
9-O- α-l- rhamnopyranosyloxyhy glucosides (7) and (7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside (8).
Compound 1:1H-NMR(500 MHz, CD3OD)δ7.11(1H, d,J =1.8 Hz, H-2'), 7.04(1H, d,J =
1.6 Hz, H_2), 6.89(1H, dd,J =8.1,1.6 Hz, H_6), 6.87(1H, dd,J=8.0,1.8 Hz, H-6'),
6.82(1H, d,J =8.1, H_5), 6.73(1H, d,J =8.0, H_5'), 4.82(1H, overlap, H-7), 4.70(1H, s,
H-7'), 4.50(1H, t,J =8.6 Hz, Ha _9), 4.40(1H, d,J =10.4 Hz, Ha _9'), 4.35(1H, d,J =
7.7 Hz, H_1''), 3.94(1H, d,J=10.4 Hz, Hb- 9'), 3.89(3H, s, 3-OMe), 3.85(3H, s, 3'-OMe),
3.80(1H, dd,J =8.6,5.8 Hz, Hb- 9), 3.69(1H, dd,J =12.0,2.2 Hz, Ha _6''), 3.52(1H, dd,J =12.0,5.6 Hz, Hb _6''), 3.40(1H, ddd,J =8.6,5.8,5.7 Hz, H-8), 3.16(2H, m, H_3'',
4''), 3.04(1H, m, H_2''), 2.91(1H, m, H-5'')；13C-NMR(125 MHz, CD3OD)δ149.31(C-3),
148.38(C-3'), 147.46(C-4'), 147.31(C-4), 133.14(C-1) and, 128.60(C-1'), 122.40(C-6'),
119.92(C-6), 116.29(C-5), 115.24(C-5'), 114.06(C-2') and, 110.76(C-2), 100.03(C-1''),
99.17(C-8'), 89.94(C-7'), 86.84(C-7), 78.32(C-3'') and, 77.95(C-5''), 74.83(C-2''),
73.30(C-9'), 72.13(C-9), 71.18(C-4''), 62.47(C-6'') and, 60.23(C-8), 56.60(3-OMe),
56.55(3'-OMe)；ESI-MS m/z 559 [M+Na]+。
Compound 2: yellow oily.HR ESI-MS spectrum display quasi-molecular ion peakm/z 529.1684 [M+Na]+, knot
It closes13C-NMR modal data speculates that molecular formula is C25H30O11(calculated value C25H30O11Na relative molecular mass 529.1686).1H-NMR
Spectrum is shown with two groups of ABX Coupling System aromatic signal δ 7.08(1H, d,J =1.8 Hz), 6.85(1H, dd,J =8.1,
1.8 Hz), 6.74(1H, d,J =8.1 Hz) and 7.04(1H, d,J =1.8 Hz), 6.89(1H, dd,J =8.2,1.8
Hz), 6.81(1H, d,J =8.2 Hz)；13C-NMR spectrum is shown with 12 fragrant carbon signals, thus it is speculated that there are two phenyl ring in structure.1H-NMR, which is composed, to be shown there are two methene proton signal δ 4.51(1H, the t being connected with oxygen,J =8.7 Hz), 3.81(1H, dd,J
=8.7,6.2 Hz) and 4.30(1H, d,J =10.2 Hz), 3.99(1H, d,J =10.2 Hz)；Two times being connected with oxygen
Methyl proton signal δ 4.85(1H, d,J =5.2 Hz) and 4.72(1H, s)；One methine proton signal δ 3.47(1H,
M).13C-NMR spectrum shows that there are two the mesomethylene carbon signal δ 73.46 and 72.31 being connected with oxygen；Two methines being connected with oxygen
Carbon signal δ 90.03 and 86.65；One methine carbon signal δ 59.79；One quaternary carbon signal δ 99.35 being connected with oxygen.It is comprehensive
Close parsing above data, thus it is speculated that compound 2 is 8'- hydroxyl -7,9':7', 9- bisepoxy lignans compound.
1H-NMR spectrum shows that there are two methoxy proton signal δ 3.89(3H, s) and 3.86(3H, s).HMBC spectrum shows δH
3.89/δC149.30, δC 149.30/δH7.04 6.81；δH 3.86/δC148.55, δC 148.55/δH7.08 6.74
Long-range coherent signal, thus it is speculated that phenyl ring 3,3' methoxy substitutions.1H-NMR spectrum is shown with sugared anomeric proton signal δ 4.27(1H, d,J
=6.2 Hz)；13C-NMR spectrum is shown with the carbon signal δ 100.55,72.08,74.42,69.21,66.35 of one group of sugar, thus it is speculated that structure
Middle presenceα- l- aralino.HMBC spectrum shows δH 4.27/δC 99.35 long-range coherent signals, thus it is speculated that 8' aralinos take
Generation.Be comprehensively compared (+) -1- hydroxyl pinoresinol, two table pinoresinol of (+) -1- hydroxyl -2,6-, (+) -1- hydroxyl -2- table pinoresinol and
(+) -1- hydroxyl -6- table pinoresinol H-7/7' ~ H-9/9'1H-NMR data and C-7/7' ~ C-9/9'13C-NMR data, root
According to H-7 and H-8 coupling constantJ =5.2 Hz, thus it is speculated that H-7 and H-8 anti-configuration；It is negative that CD spectrum is shown with 241nmcottonEffect.
Integration analysis above data, authenticating compound 2 are (+) -8'- hydroxyl rosin element -8'-O-α- l- arabopyranose glycosides ((+)-
8'-hydroxypinoresinol-8'-O-α- l-arabinopyranoside).The compound has no document report so far, is
Noval chemical compound.
1H-NMR(500 MHz, CD3OD)δ7.08(1H, d,J =1.8 Hz, H-2'), 7.04(1H, d,J =1.8 Hz,
H_2), 6.89(1H, dd,J =8.2,1.8 Hz, H_6), 6.85(1H, dd,J =8.1,1.8 Hz, H-6'), 6.81(1H, d,J =8.2 Hz, H-5), 6.74(1H, d,J =8.2 Hz, H-5'), 4.85(1H, d,J =5.2 Hz, H-7), 4.72(1H,
S, H-7'), 4.51(1H, t,J =8.7 Hz, Ha _9), 4.30(1H, d,J =10.2 Hz, Ha _9'), 4.27(1H, d,J =
6.2 Hz, H_1''), 3.99(1H, d,J=10.2 Hz, Hb- 9'), 3.89(3H, s, 3-OMe), 3.86(3H, s, 3'-OMe),
3.81(1H, dd,J =8.7,6.2 Hz, Hb- 9), 3.65(1H, m, H-4''), 3.60(1H, dd,J =12.4,3.3 Hz, H_
5''), 3.47(1H, m, H-8), 3.29(2H, m, H-2'', 3''), 3.14(1H, dd,J =12.4,1.6 Hz, H_5'')；13C-NMR(125 MHz, CD3OD)δ149.30(C-3), 148.55(C-3'), 147.40(C-4'), 147.35(C-4),
133.13(C-1), 128.70(C-1'), 121.73(C-6'), 119.91(C-6) and, 116.24(C-5), 115.40(C-5'),
113.35(C-2'), 110.85(C-2), 100.55(C-1''), 99.35(C-8') and, 90.03(C-7'), 86.65(C-7),
74.42(C-3''), 73.46(C-9'), 72.31(C-9), 72.08(C-2'') and, 69.21(C-4''), 66.35(C-5''),
59.79(C-8), 56.59(3-OMe), 56.52(3'-OMe)；HR ESI-MS m/z 529.1684 [M+Na]+(calculated value
C25H30O11Na relative molecular mass 529.1686).
Compound 3: yellow oily.HR ESI-MS spectrum display quasi-molecular ion peakm/z 529.1672 [M+Na]+, knot
It closes13C-NMR modal data speculates that molecular formula is C25H30O11(calculated value C25H30O11Na relative molecular mass 529.1686).1H-NMR
Spectrum is shown with two groups of ABX Coupling System aromatic signal δ 7.08(1H, d,J =1.8 Hz), 6.85(1H, dd,J =8.1,
1.8 Hz), 6.74(1H, d,J =8.1 Hz) and 7.05(1H, d,J =1.8 Hz), 6.89(1H, dd,J =8.1,1.8
Hz), 6.81(1H, d,J =8.1 Hz)；13C-NMR spectrum is shown with 12 fragrant carbon signals, thus it is speculated that there are two phenyl ring in structure.1H-NMR, which is composed, to be shown there are two methene proton signal δ 4.49(1H, the t being connected with oxygen,J =8.6 Hz), 3.81(1H, dd,J
=8.6,5.9 Hz) and 4.31(1H, d,J =10.2 Hz), 3.95(1H, d,J =10.2 Hz)；Two times being connected with oxygen
Methyl proton signal δ 4.82(1H, overlap) and 4.72(1H, s)；One methine proton signal δ 3.41(1H, ddd,J
=8.6,5.9,5.8 Hz)；13C-NMR spectrum shows that there are two the mesomethylene carbon signal δ 73.51 and 72.14 being connected with oxygen；Two with
The connected methine carbon signal δ 89.74 and 87.00 of oxygen；One methine carbon signal δ 60.08；One quaternary carbon being connected with oxygen
Signal δ 99.19.Integration analysis above data, thus it is speculated that compound 3 is 8'- hydroxyl -7,9':7', 9- bisepoxy lignans chemical combination
Object.
1H-NMR spectrum shows that there are two methoxy proton signal δ 3.89(3H, s) and 3.85(3H, s).HMBC spectrum display δH
3.89/δC149.33, δC 149.33/δH7.05 6.81；δH 3.85/δC148.46, δC 148.46/δH7.08 6.74
Long-range coherent signal, thus it is speculated that phenyl ring 3,3' methoxy substitutions.1H-NMR spectrum is shown with sugared anomeric proton signal δ 4.34(1H, d,J
=7.3 Hz)；13C-NMR spectrum is shown with the carbon signal δ 100.70,74.53,77.82,70.83,66.52 of one group of sugar, thus it is speculated that structure
In there are β-d- xylosyls.HMBC spectrum shows δH 4.34/δC 99.19 long-range coherent signals, thus it is speculated that 8' xylosyls replace.It is comprehensive
Compare (+) -1- hydroxyl pinoresinol, two table pinoresinol of (+) -1- hydroxyl -2,6-, (+) -1- hydroxyl -2- table pinoresinol and (+) -1-
Hydroxyl -6- table pinoresinol H-7/7' ~ H-9/9'1H-NMR data and C-7/7' ~ C-9/9'13C-NMR data, according to H-7 and
H-8 coupling constantJ=5.8 Hz, thus it is speculated that H-7 and H-8 anti-configuration；It is negative that CD spectrum is shown with 242nmcottonEffect.Integration analysis
Above data, authenticating compound 3 are (+) -8'- hydroxyl rosin element -8'-O- β-d- xylopyranose glucosides ((+) -8'-
hydroxypinoresinol-8'-O- β-d-xylopyranoside).The compound has no document report so far, is new chemical combination
Object.
1H-NMR(500 MHz, CD3OD)δ7.08(1H, d,J =1.8 Hz, H-2'), 7.05(1H, d,J =1.8 Hz,
H_2), 6.89(1H, dd,J =8.1,1.8 Hz, H_6), 6.85(1H, dd,J=8.1,1.8 Hz, H-6'), 6.81(1H, d,J =8.1 Hz, H_5), 6.74(1H, d,J =8.1 Hz, H_5'), 4.82(1H, overlap, H-7), 4.72(1H, s, H-
7'), 4.49(1H, t,J =8.6 Hz, Ha _9), 4.34(1H, d,J =7.3 Hz, H_1''), 4.31(1H, d,J = 10.2
Hz, Ha _9'), 3.95(1H, d,J=10.2 Hz, Hb- 9'), 3.89(3H, s, 3-OMe), 3.85(3H, s, 3'-OMe) and, 3.81
(1H, dd,J =8.6,5.9 Hz, Hb- 9), 3.63(1H, dd,J =11.4,5.2 Hz, H_5''), 3.41(1H, ddd,J =
8.0,5.8,5.8 Hz, H-8), 3.32(1H, m, H_4''), 3.12(1H, t,J =8.8 Hz, H_3''), 2.99(1H, dd,J
=8.8,7.3 Hz, H_2''), 2.86(1H, dd,J =11.4,10.1 Hz, H_5'')；13C-NMR(125 MHz, CD3OD)δ
149.33(C-3), 148.46(C-3'), 147.41(C-4,4'), 133.10(C-1) and, 128.72(C-1'), 122.01(C-
6'), 119.98(C-6), 116.24(C-5), 115.35(C-5') and, 113.63(C-2'), 110.82(C-2) and, 100.70(C-
1''), 99.19(C-8'), 89.74(C-7'), 87.00(C-7) and, 77.82(C-3''), 74.53(C-2'') and, 73.51(C-
9'), 72.14(C-9), 70.83(C-4''), 66.52(C-5'') and, 60.08(C-8), 56.60(3-OMe) and, 56.52(3'-
OMe)；HR ESI-MS m/z 529.1672 [M+Na]+(calculated value C25H30O11Na relative molecular mass 529.1686).
Compound 4:1H-NMR(500 MHz, CD3OD)δ6.58(1H, s, H-2'), 6.43(2H, s, H-2,6), 4.42
(1H, d,J =6.1 Hz, H-7), 4.29(1H, d,J =7.8 Hz, H-1''), 3.89(1H, dd,J =9.8,5.6 Hz,
Ha- 9), 3.85(3H, s, 3'-OCH3), 3.84(1H, dd,J =11.0,1.6 Hz, Ha- 6''), 3.75(6H, s, 3,5-
OCH3), 3.66(2H, m, H_9'), 3.54(1H, dd,J =11.0,6.6 Hz, Hb- 6''), 3.46(1H, dd,J =9.8,
4.0 Hz, Hb- 9), 3.37(1H, t,J =8.8 Hz, H-3''), 3.35(3H, s, 5'-OCH3), 3.29(1H, t,J = 8.8
Hz, H-4''), 3.25(1H, m, H-5''), 3.24(1H, m, H-2''), 2.72(1H, dd,J =15.2,4.7 Hz, Ha _7'),
2.61(1H, dd,J =15.2,11.6 Hz, Hb _7'), 2.09(1H, m, H_8), 1.71(1H, m, H_8')；13C-NMR(125
MHz, CD3OD)δ148.99(C-3,5), 148.63(C-3') and, 147.59(C-5'), 139.32(C-1) and, 138.90(C-4'),
134.53(C-4), 130.21(C-1'), 126.41(C-6'), 107.88(C-2') and, 106.95(C-2,6), 104.81(H-
1''), 78.23(H-3''), 77.92(H-5''), 75.17(H-2'') and, 71.67(H-4''), 71.54(C-9) and, 66.25(C-
9'), 62.83(H-6''), 60.19(5'-OCH3), 56.88(3,5-OCH3), 56.62(3'-OCH3), 46.68(C-8),
42.76(C-7), 40.62(C-8'), 33.80(C-7')；ESI-MS m/z 605 [M+Na]+。
Compound 5:1H-NMR(500 MHz, C5D5N)δ7.31(1H, br s, H-2), 7.21(1H, d,J=8.0 Hz,
H_5), 7.02(1H, br d,J=8.0 Hz, H_6), 6.86(2H, s, H-2', 5'), 4.64(1H, d,J =7.5 Hz, H-
1''), 4.60(1H, br d,J=10.6 Hz, Ha- 9), 4.56(1H, d,J=10.8 Hz, H-7), 4.29(1H, dd,J =
10.6,5.1 Hz, Ha- 5''), 4.26(2H, m, H_9'), 4.20(1H, m, H_4''), 4.13(1H, t,J =8.7 Hz, H-
3''), 4.05(1H, dd,J=8.7,7.5 Hz, H_2''), 3.81(3H, s, 3'-OCH3), 3.73(3H, s, 3-OCH3),
3.65(1H, dd,J=10.6,2.1 Hz, Hb- 9), 3.62(1H, t,J=10.6 Hz, Hb- 5''), 3.34(1H, dd,J =
15.8,12.2 Hz, Ha _7'), 3.15(1H, dd,J =15.8,4.1 Hz, Hb _7'), 2.50(1H, m, H_8'), 2.40
(1H, m, H_8)；13C-NMR(125 MHz, C5D5N)δ148.58(C-3), 147.02(C-3'), 146.43(C-4), 146.08
(C-4'), 137.96(C-1), 134.18(C-1'), 128.24(C-6') and, 122.68(C-6), 117.96(C-5') and, 116.60
(C-5), 114.52(C-2), 112.70(C-2'), 106.07(C-1'') and, 78.43(C-3''), 75.12(C-2'') and, 71.17
(C-4''), 68.70(C-9), 67.22(C-5''), 64.34(C-9') and, 56.19(3'-OCH3), 56.00(3-OCH3), 47.48
(C-7), 45.54(C-8), 39.32(C-8'), 33.85(C-7')；ESI-MS m/z 515 [M+Na]+。
Compound 6:1H-NMR(500 MHz, CD3OD)δ6.74(1H, d,J=8.0 Hz, H_5), 6.72(1H, d,J =
1.9 Hz, H_2), 6.65(1H, s, H-2'), 6.59(1H, dd,J=8.0,1.9 Hz, H_6), 6.18(1H, s, H-5'),
4.00(1H, d,J =7.6 Hz, H-1''), 3.81(3H, s, 3'-OCH3), 3.80(3H, s, 3-OCH3), 3.79(1H, m, Ha _
5''), 3.78(1H, m, Ha _9'), 3.76(1H, d,J =10.0 Hz, H-7), 3.72(1H, dd,J =10.3,5.0 Hz,
Hb _9'), 3.71(1H, dd,J =10.4,3.6 Hz, Ha _9), 3.60(1H, dd,J=10.4,2.6 Hz, Hb- 9), 3.46
(1H, ddd,J =10.2,8.9,5.4 Hz, H_4''), 3.24(1H, t,J =8.9 Hz, H-3''), 3.16(1H, dd,J =
8.9,7.6 Hz, H_2''), 3.03(1H, dd,J=11.3,10.2 Hz, Hb _5''), 2.87(1H, dd,J =15.8,11.2
Hz, Ha _7'), 2.75(1H, dd,J =15.8,4.4 Hz, Hb _7'), 1.99(1H, m, H_8'), 1.92(1H, m, H_8)；13C-NMR(125 MHz, CD3OD)δ148.91(C-3), 147.28(C-3'), 145.98(C-4), 145.29(C-4'),
138.73(C-1), 133.80(C-1'), 129.23(C-6'), 123.20(C-6) and, 117.43(C-5'), 116.06(C-5),
114.26(C-2), 112.42(C-2'), 104.73(C-1''), 77.98(C-3'') and, 74.89(C-2''), 71.25(C-
4''), 70.34(C-9), 67.00(C-5''), 65.47(C-9') and, 56.42(3,3'-OCH3), 48.49(C-7), 45.60(C-
8), 40.71(C-8'), 33.73(C-7')；ESI-MS m/z 515 [M+Na]+。
Compound 7:1H-NMR(500 MHz, CD3OD)δ6.97(1H, d,J =1.7 Hz, H-2), 6.85(1H, dd,J
=8.2,1.8 Hz, H-6), 6.78(1H, d,J =8.2 Hz, H-5), 6.59(1H, s, H-6'), 6.58(1H, s, H-2'),
5.46(1H, d,J =6.5 Hz, H-7), 4.73(1H, d,J =1.0 Hz, H-1''), 3.88(1H, dd,J =9.8,7.8
Hz, Ha _9), 3.83(3H, s, 3-OMe), 3.82(1H, dd,J =3.2,1.6 Hz, H-2''), 3.72(1H, dd,J =9.8,
5.2 Hz, Hb _9), 3.62(1H, m, H-8), 3.61(1H, dd,J =9.4,3.2 Hz, H-3''), 3.55(2H, t,J = 6.6
Hz, H _9'), 3.55(1H, m, H-5''), 3.38(1H, t,J =9.4 Hz, H-4''), 2.57(2H, t,J=7.4 Hz, H_7'), 1.80(2H, m, H _8'), 1.25(3H, d,J =6.2 Hz, H-6'')；13C-NMR(125 MHz, CD3OD)δ149.12
(C-3), 147.51(C-4), 146.47(C-4'), 141.91(C-3') and, 136.83(C-1'), 134.78(C-1) and, 129.47
(C-5'), 119.83(C-6), 117.20(C-2'), 116.45(C-6') and, 116.17(C-5), 110.57(C-2) and, 101.70
(C-1''), 89.20(C-7), 73.86(C-4''), 72.50(C-3'') and, 72.19(C-2''), 70.46(C-9) and, 70.17(C-
5''), 62.28(C-9'), 56.48(3-OMe), 53.03(C-8) and, 35.72(C-8'), 32.70(C-7') and, 18.01(C-
6'')；ESI-MS m/z 515 [M+Na]+。
Compound 8:1H-NMR(500 MHz, CD3OD)δ6.95(1H, d,J=1.8 Hz, H_2), 6.83(1H, dd,J =
8.2,1.8 Hz, H-6), 6.76(1H, d,J=8.2 Hz, H_5), 6.75(2H, s, H-2', 6'), 5.49(1H, d,J =
6.3 Hz, H_7), 4.25(1H, d,J =7.8 Hz, H_1''), 3.93(1H, dt,J=9.6,6.4 Hz, Ha- 9'), 3.87
(1H, dd,J =11.9,2.0 Hz, Ha- 6''), 3.86(3H, s, 3'-OCH3), 3.84(1H, dd,J=11.0,4.8 Hz,
Ha- 9), 3.82(3H, s, 3-OCH3), 3.76(1H, dd,J=11.0,7.2 Hz, Hb _9), 3.67(1H, dd,J=11.9,
5.6 Hz, H _6''), 3.54(1H, dt,J =9.6,6.5 Hz, Hb _9'), 3.47(1H, br q,J =6.4 Hz, H_8),
3.35(1H m, H_3''), 3.28(1H, m, H_4''), 3.25(1H, ddd,J =11.6,5.6,2.0 Hz, H_5''), 3.20
(1H, dd,J =8.8,7.8 Hz, H_2''), 2.68(2H, t,J =7.4 Hz, H_7'), 1.91(2H, m, H_8')；13C-NMR
(125 MHz, CD3OD)δ149.11(C-3), 147.57(C-4), 147.54(C-4'), 145.20(C-3') and, 136.84(C-
1'), 134.84(C-1), 129.91(C-5'), 119.75(C-6) and, 118.12(C-6'), 116.16(C-1) and, 114.35(C-
2'), 110.64(C-2), 104.52(C-1''), 89.00(C-7) and, 78.18(C-3''), 77.93(C-5'') and, 75.21(C-
2''), 71.73(C-4''), 69.93(C-9'), 65.04(C-9) and, 62.82(C-6''), 56.85(3'-OCH3), 56.42(3-
OCH3), 55.45(C-8), 32.93(C-7'), 32.89(C-8')；ESI-MS m/z 545 [M+Na]+。
Embodiment 8
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component is to lipopolysaccharide-induced mouse macrophage strain RAW
264.7 pro-inflammatory cytokine tumor necrosis factor-alphas, Interleukin -1β and interleukin-6 generate inhibitory activity measurement
Mouse macrophage strain RAW 264.7 is inoculated in (green containing 100 units/mL containing 10% fetal calf serum DMEM culture solution
Mycin, gentamicin 100uG/mL it in), sets containing 5%CO2Regular growth culture is carried out in 37 DEG C of constant incubators.When experiment
The good cell EDTA digestive juice digestion of growth conditions is taken, is counted.It is 8 × 10 by density5The mouse macrophage strain of a/ml
264.7 250 μ l of RAW is seeded on 48 well culture plates, is placed in containing 5 %CO237 DEG C of constant incubators in cultivate 2 days,
The culture medium for the willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component that 20 μ l contain various concentration is added in each hole,
30 μ l contain the culture medium of 100 ng/mL LPS, are placed in containing 5%CO237 DEG C of constant incubators in cultivate 12 hours, supernatant
Liquid detects tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 content with ELISA kit.It the results are shown in Table 3.
3 willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component of table is to lipopolysaccharide-induced mouse macrophage
Strain
The influence that 264.7 proinflammatory cytokine of RAW is generated by tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Embodiment 9
(+) -8'- hydroxyl rosin element -8'-O- β-d- glucopyranoside is to lipopolysaccharide-induced mouse macrophage strain
264.7 proinflammatory cytokine of RAW generates inhibitory activity measurement because of tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Mouse macrophage strain RAW 264.7 is inoculated in (green containing 100 units/mL containing 10% fetal calf serum DMEM culture solution
Mycin, gentamicin 100uG/mL it in), sets containing 5%CO2Regular growth culture is carried out in 37 DEG C of constant incubators.When experiment
The good cell EDTA digestive juice digestion of growth conditions is taken, is counted.It is 8 × 10 by density5The mouse macrophage strain of a/ml
264.7 250 μ l of RAW is seeded on 48 well culture plates, is placed in containing 5 %CO237 DEG C of constant incubators in cultivate 2 days,
(+) -8'- hydroxyl rosin element -8'- that 20 μ l contain various concentration is added in each holeOThe culture of-β-d- glucopyranoside
Base, 30 μ l contain the culture medium of 100 ng/mL LPS, are placed in containing 5%CO237 DEG C of constant incubators in cultivate 12 hours,
Supernatant detects tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 content with ELISA kit.It the results are shown in Table 4.
Table 4 (+) -8'- hydroxyl rosin element -8'-O- β-d- glucopyranoside is to lipopolysaccharide-induced mouse macrophage
The influence that strain 264.7 proinflammatory cytokine of RAW is generated by tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Embodiment 10
(7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside is huge thermophilic to lipopolysaccharide-induced mouse
264.7 proinflammatory cytokine of cell strain RAW generates inhibitory activity measurement because of tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Mouse macrophage strain RAW 264.7 is inoculated in (green containing 100 units/mL containing 10% fetal calf serum DMEM culture solution
Mycin, gentamicin 100uG/mL it in), sets containing 5%CO2Regular growth culture is carried out in 37 DEG C of constant incubators.When experiment
The good cell EDTA digestive juice digestion of growth conditions is taken, is counted.It is 8 × 10 by density5The mouse macrophage strain of a/ml
264.7 250 μ l of RAW is seeded on 48 well culture plates, is placed in containing 5 %CO237 DEG C of constant incubators in cultivate 2 days,
20 μ l are added in each hole and contain (the 7 of various concentrationR,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside
Culture medium, 30 μ l contain the culture medium of 100 ng/mL LPS, are placed in containing 5%CO237 DEG C of constant incubators in cultivate 12
Hour, supernatant detects tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 content with ELISA kit.It the results are shown in Table 5.
Table 5 (7R,8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-d- glucopyranoside is to lipopolysaccharide-induced mouse
The influence that 264.7 proinflammatory cytokine of macrophage strain RAW is generated by tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Embodiment 11
(+)-basilima sorbifolia Shu Huan lignanoid -9-O-β-d- glucopyranoside is to lipopolysaccharide-induced mouse macrophage strain
264.7 proinflammatory cytokine of RAW generates inhibitory activity measurement because of tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Mouse macrophage strain RAW 264.7 is inoculated in (green containing 100 units/mL containing 10% fetal calf serum DMEM culture solution
Mycin, gentamicin 100uG/mL it in), sets containing 5%CO2Regular growth culture is carried out in 37 DEG C of constant incubators.When experiment
The good cell EDTA digestive juice digestion of growth conditions is taken, is counted.It is 8 × 10 by density5The mouse macrophage strain of a/ml
264.7 250 μ l of RAW is seeded on 48 well culture plates, is placed in containing 5 %CO237 DEG C of constant incubators in cultivate 2 days,
(+)-basilima sorbifolia Shu Huan lignanoid -9- that 20 μ l contain various concentration is added in each holeO-The culture of β-d- glucopyranoside
Base, 30 μ l contain the culture medium of 100 ng/mL LPS, are placed in containing 5%CO237 DEG C of constant incubators in cultivate 12 hours,
Supernatant detects tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 content with ELISA kit.It the results are shown in Table 6.
Table 6 (+)-basilima sorbifolia Shu Huan lignanoid -9-O-β-d- glucopyranoside is huge thermophilic thin to lipopolysaccharide-induced mouse
The influence that born of the same parents' strain RAW264.7 proinflammatory cytokine is generated by tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Embodiment 12
(+)-isolariciresinol -9-O- β-d- xylopyranose glucosides is to lipopolysaccharide-induced mouse macrophage strain RAW
264.7 proinflammatory cytokines generate inhibitory activity measurement because of tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Mouse macrophage strain RAW 264.7 is inoculated in (green containing 100 units/mL containing 10% fetal calf serum DMEM culture solution
Mycin, gentamicin 100uG/mL it in), sets containing 5%CO2Regular growth culture is carried out in 37 DEG C of constant incubators.When experiment
The good cell EDTA digestive juice digestion of growth conditions is taken, is counted.It is 8 × 10 by density5The mouse macrophage strain of a/ml
264.7 250 μ l of RAW is seeded on 48 well culture plates, is placed in containing 5 %CO237 DEG C of constant incubators in cultivate 2 days,
(+)-isolariciresinol -9- that 20 μ l contain various concentration is added in each holeOThe culture medium of-β-d- xylopyranose glucosides, 30 μ
L contains the culture medium of 100 ng/mL LPS, is placed in containing 5%CO237 DEG C of constant incubators in cultivate 12 hours, supernatant
With ELISA kit detection tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 content.It the results are shown in Table 7.
Table 7 (+)-isolariciresinol -9-O- β-d- xylopyranose glucosides is to lipopolysaccharide-induced mouse macrophage strain
RAW 264.7
The influence that proinflammatory cytokine is generated by tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Embodiment 13
(+) -8'- hydroxyl rosin element -8'-O-α- l- arabopyranose glycosides is to lipopolysaccharide-induced mouse macrophage strain
264.7 proinflammatory cytokine of RAW generates inhibitory activity measurement because of tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Mouse macrophage strain RAW 264.7 is inoculated in (green containing 100 units/mL containing 10% fetal calf serum DMEM culture solution
Mycin, gentamicin 100uG/mL it in), sets containing 5%CO2Regular growth culture is carried out in 37 DEG C of constant incubators.When experiment
The good cell EDTA digestive juice digestion of growth conditions is taken, is counted.It is 8 × 10 by density5The mouse macrophage strain of a/ml
264.7 250 μ l of RAW is seeded on 48 well culture plates, is placed in containing 5 %CO237 DEG C of constant incubators in cultivate 2 days,
(+) -8'- hydroxyl rosin element -8'- that 20 μ l contain various concentration is added in each holeO-αThe culture of-l- arabopyranose glycosides
Base, 30 μ l contain the culture medium of 100 ng/mL LPS, are placed in containing 5%CO237 DEG C of constant incubators in cultivate 12 hours,
Supernatant detects tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 content with ELISA kit.It the results are shown in Table 8.
Table 8 (+) -8'- hydroxyl rosin element -8'-O-α- l- arabopyranose glycosides is huge thermophilic thin to lipopolysaccharide-induced mouse
The influence that born of the same parents' strain 264.7 proinflammatory cytokine of RAW is generated by tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Embodiment 14
(+) -8'- hydroxyl rosin element -8'-O- β-d- xylopyranose glucosides is to lipopolysaccharide-induced mouse macrophage strain RAW
264.7 proinflammatory cytokines generate inhibitory activity measurement because of tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Mouse macrophage strain RAW 264.7 is inoculated in (green containing 100 units/mL containing 10% fetal calf serum DMEM culture solution
Mycin, gentamicin 100uG/mL it in), sets containing 5%CO2Regular growth culture is carried out in 37 DEG C of constant incubators.When experiment
The good cell EDTA digestive juice digestion of growth conditions is taken, is counted.It is 8 × 10 by density5The mouse macrophage strain of a/ml
264.7 250 μ l of RAW is seeded on 48 well culture plates, is placed in containing 5 %CO237 DEG C of constant incubators in cultivate 2 days,
(+) -8'- hydroxyl rosin element -8'- that 20 μ l contain various concentration is added in each holeOThe culture medium of-β-d- xylopyranose glucosides,
30 μ l contain the culture medium of 100 ng/mL LPS, are placed in containing 5%CO237 DEG C of constant incubators in cultivate 12 hours, supernatant
Liquid detects tumor necrosis factor-alpha, Interleukin -1β and interleukin-6 content with ELISA kit.It the results are shown in Table 9.
Table 9 (+) -8'- hydroxyl rosin element -8'-O- β-d- xylopyranose glucosides is to lipopolysaccharide-induced mouse macrophage strain
The influence that 264.7 proinflammatory cytokine of RAW is generated by tumor necrosis factor-alpha, Interleukin -1β and interleukin-6
Embodiment 15
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component pharmaceutically acceptable carrier or excipient system
Standby pharmaceutical preparation.These pharmaceutical preparations are selected from following dosage form: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, bubble
Effervescent tablet, capsule, hard capsule, soft capsule, microcapsules, microspheres agent, granule, pill, pill, dissipates sublingual tablets
Agent, paste, oral solution, suspension, solution, aerosol, injection, emulsion for injection, freeze-dried powder can also be made as needed
For at sustained release or controlled release preparation, pharmaceutically acceptable carrier, the pharmaceutically acceptable load can be added when preparing pharmaceutical preparation
Body comes from: antioxidant, chelating agent, surfactant, filler, disintegrating agent, wetting agent, solvent, slow-release material, enteric material,
PH adjusting agent, corrigent, pigment etc., common carrier such as: mannitol, dextran, lactose, glucose, sorbierite, xylose
Alcohol, water for injection, injection ethyl alcohol, sodium chloride, silicon derivative, cellulose, cellulose derivative, gelatin, polyvinylpyrrolidine
Ketone, glycerol, Tween 80, agar, calcium carbonate, polyethylene glycol, cyclodextrin, phospholipid material, talcum powder, magnesium stearate, stearic acid
Calcium.Above-mentioned preparation process is this field routine operation, is not added repeats herein.
Embodiment 16
Willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component is that pharmaceutical preparation made from raw material not only includes list
The pharmaceutical preparation for solely using willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component further includes addition willow leaf meadow sweet stem
Pharmaceutical preparation of the branch resisting rheumatoid arthritis active component as active constituent.
Claims (6)
1. a kind of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component, it is characterised in that from willow leaf meadow sweet stem branch
Isolated total lignan glycosides effective part is extracted, wherein (+) -8'- hydroxyl rosin element -8'-O- β-D- glucopyranoside, (7R,
8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-D- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O- β-D- pyrans
The sum of the weight of glucoside and (+)-isolariciresinol -9-O- β-D- xylopyranose glucosides accounts for the anti-class wind of willow leaf meadow sweet stem branch
The 40%~50% of wet arthritis active component total weight, is prepared by the following method to obtain: willow leaf meadow sweet stem branch adds
60% alcohol reflux extracts three times, each dosage be by kilogram in terms of 8 times of willow leaf meadow sweet stem branch weight volumes in litres, often
Secondary 2 hours, filtration, filtrate merge, ethyl alcohol is recovered under reduced pressure and obtains extract, extract adds water to make to dissolve, dosage be by kilogram in terms of willow
The volume in litres of 0.5 times of leaf meadow sweet stem branch weight fills macroporous absorbent resin through large pore resin absorption column D101 chromatography
D101 volume be by kilogram in terms of 0.5 times of willow leaf meadow sweet stem branch weight volume in litres, nothing close to eluent is eluted with water
Color discards eluent, closely colourless to eluent with 20% ethanol elution, discards eluent, with 50% ethanol elution to eluent
It is close colourless, eluent is collected, is concentrated under reduced pressure, dry willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component.
2. willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component according to claim 1, it is characterised in that main
Wanting ingredient includes (+) -8'- hydroxyl rosin element -8'-O- β-D- glucopyranoside, (7R, 8S)-dihydro dehydrodiconiferyl alcohol -
9'-O- β-D- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O- β-D- glucopyranoside, (+)-different larch
Rouge element -9-O- β-D- xylopyranose glucosides, (+) -8'- hydroxyl rosin element -8'-O- α-L- arabopyranose glycosides and (+) -8'- hydroxyl
Base rosin element -8'-O- β-D- xylopyranose glucosides.
3. a kind of preparation method of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component, it is characterised in that including following
Step: willow leaf meadow sweet stem branch add 60% alcohol reflux extract three times, each dosage be by kilogram in terms of willow leaf meadow sweet stem branch weight
8 times of volumes in litres of amount, 2 hours every time, filtration, filtrate merged, and ethyl alcohol is recovered under reduced pressure and obtains extract, extract adds water to make
Dissolution, dosage be by kilogram in terms of 0.5 times of willow leaf meadow sweet stem branch weight volume in litres, through large pore resin absorption column D101
Chromatography, filling macroporous absorbent resin D101 volume be by kilogram in terms of 0.5 times of willow leaf meadow sweet stem branch weight volume in litres,
It is eluted with water closely colourless to eluent, discards eluent, it is closely colourless to eluent with 20% ethanol elution, eluent is discarded, is used
50% ethanol elution is closely colourless to eluent, collects eluent, is concentrated under reduced pressure, dry willow leaf meadow sweet stem branch resisting rheumatoid
Arthritis active component.
4. the preparation method of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component according to claim 3,
It is characterized in that (+) -8'- hydroxyl rosin element -8'-O- β-D- glucopyranoside, (7R, 8S)-dihydro in the active component of preparation
Dehydrodiconiferyl alcohol -9'-O- β-D- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O- β-D- glucopyranoside
The sum of the weight of (+)-isolariciresinol -9-O- β-D- xylopyranose glucosides accounts for willow leaf meadow sweet stem branch anti-rheumatoid arthritis
The 40%~50% of scorching active component total weight.
5. the preparation method of willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component according to claim 3,
Be characterized in that preparation active component main component include (+) -8'- hydroxyl rosin element -8'-O- β-D- glucopyranoside,
(7R, 8S)-dihydro dehydrodiconiferyl alcohol -9'-O- β-D- glucopyranoside, (+)-basilima sorbifolia Shu Huan lignanoid -9-O- β-D-
Glucopyranoside, (+)-isolariciresinol -9-O- β-D- xylopyranose glucosides, (+) -8'- hydroxyl rosin element -8'-O- α-L-
Arabopyranose glycosides and (+) -8'- hydroxyl rosin element -8'-O- β-D- xylopyranose glucosides.
6. willow leaf meadow sweet stem branch resisting rheumatoid arthritis active component described in claim 1 treats rheumatoid in preparation
Application in arthritis product.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610086918 | 2016-02-16 | ||
| CN2016100869181 | 2016-02-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105796680A CN105796680A (en) | 2016-07-27 |
| CN105796680B true CN105796680B (en) | 2019-07-19 |
Family
ID=56460445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610201656.9A Expired - Fee Related CN105796680B (en) | 2016-02-16 | 2016-04-05 | Willow leaf meadow sweet stem branch resisting rheumatoid disease active component and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105796680B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110559307A (en) * | 2019-09-30 | 2019-12-13 | 江南大学 | albizzia julibrissin new lignan compound and new application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585311B (en) * | 2013-10-31 | 2015-07-29 | 泰山医学院 | A kind of preparation method of Spiraea alpina extract |
-
2016
- 2016-04-05 CN CN201610201656.9A patent/CN105796680B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN105796680A (en) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lam et al. | α-Glucosidase inhibitors from the seeds of Syagrus romanzoffiana | |
| CA2932187C (en) | New salvianolic acid compound t, preparation method therefor, and use thereof | |
| Liu et al. | An in vivo and in vitro assessment of the anti-inflammatory, antinociceptive, and immunomodulatory activities of Clematis terniflora DC. extract, participation of aurantiamide acetate | |
| CN104415045B (en) | A kind of pharmaceutical composition | |
| CN106967147B (en) | C27Spirostan type steroid saponin compounds and its pharmaceutical composition and its application | |
| ES2550335T3 (en) | Fraxinus excelsior seed extract and therapeutic applications for it | |
| CN101279964A (en) | Guaiane type sesquiterpenes, preparation and medical use thereof | |
| CN101780070B (en) | Pharmaceutical composition for treating diabetic nephropathy and preparation method thereof | |
| JP5622222B2 (en) | Hypolipidemic composition and use thereof | |
| Sun et al. | Diverse sesquiterpenoids and polyacetylenes from Atractylodes lancea and their anti-osteoclastogenesis activity | |
| KR20190105635A (en) | Extract of Ginseng Plant, and its Pharmaceutical Composition and Use | |
| CN105796680B (en) | Willow leaf meadow sweet stem branch resisting rheumatoid disease active component and its preparation method and application | |
| CN105560445B (en) | Willow leaf japanese spiraea root resisting rheumatoid disease active component and its preparation method and application | |
| KR20180040756A (en) | Skin whitening composition comprising an extract of coixlachryma-jobi var. mayuen | |
| CN105503990A (en) | Novel withanolides compound as well as preparation method and medical application thereof | |
| CN101693059B (en) | Preparation method of rose polyphenol and application thereof in gynaecology and obstetrics | |
| JP2023182502A (en) | Use of effective part extract of monochasma savatieri franch.in preparation of drug for treating inflammatory disease or tumor | |
| CN103739660B (en) | A kind of compound, its extracting method, its application preparing antitumor drug and antitumor drug of preparation thereof | |
| CN106928299A (en) | One class derives from the compound of the root bark of Chinese wolf-berry, its preparation method and the application in terms of hypoglycemic | |
| KR100633096B1 (en) | Blood vessel relaxational agent containing decursin or decursinol angelate | |
| CN104189346A (en) | New pharmaceutical composition capable of promoting gastrointestinal motility and preparation method thereof | |
| CN101570485B (en) | Sugar alcohol ester of long-chain fatty acid, separation and extraction method thereof and application thereof in inhibiting the activity of aromatizing enzyme | |
| CN106074579B (en) | A kind of application of phenylpropanoids in the drug for preparing treatment diseases associated with inflammation | |
| CN108948040A (en) | The Germacrane Sesquiterpenoids compound extracted in a kind of Carpesium cernuum Linn and its application | |
| CN113264975B (en) | An extract with antiinflammatory activity extracted from fructus Rosae Normalis rhizome and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190719 Termination date: 20210405 |